Monday, August 15, 2022

561.316.3330

American Gene Technologies Reports HIV Cure Program Releases Initial Clinical Trial Data

Latest Posts

Lytix Biopharma Announced Data from its ATLAS-IT-04 Trial

The ATLAS-IT-04 trial was an open-label, exploratory, Phase II trial assessing the effect of LTX-315 when used in combination with ACT in patients with metastatic STS. ACT with tumor infiltrating lymphocytes (TILs) is a potent treatment that can induce complete and durable tumor regression as documented in patients with melanoma. The use of ACT with TILs for patients with advanced STS has not previously been reported.

Telehealth Post Pandemic Concerns By Mark Kestner Chief Innovation Officer for MediGuru

The expression “desperate times call for desperate measures” aptly explains developments in the field of telehealth during the COVID-19 pandemic. In order to serve those forced to stay in place by the pandemic, healthcare regulators made a number of concessions that loosened controls related to patient privacy and data security in an effort to boost accessibility. In essence, telehealth practices that were a concern prior to Covid were, for the sake of serving patients, deemed acceptable.

Alleviating Transportation Woes: Technology is likely a Silver Bullet, for the Transportation Industry and Beyond By: PJ Piper, Founder & CEO, Far UV Technologies

March of 2020 was a tipping point: The sudden and surreal realization of just how perilous the human journey can be, hanging by the thinnest of threads. While the world tried to understand what the Covid-19 pandemic meant for the future, billions of people immediately learned how easily dangerous invisible pathogens could upend life, literally on a dime.

Kymanox Announces First Kymanox Executive Advisor: Fran DeGrazio

Fran DeGrazio has over 35 years of experience in technical product development, quality, regulatory, marketing, and business strategy, serving most recently as the Chief Scientific Officer at West Pharmaceutical Services.

American Gene Technologies (AGT) announced today that the Data and Safety Monitoring Board (DSMB) voted unanimously to continue AGT’s HIV cure program without modification after safety analysis of the participant’s data revealed no adverse effects from the treatment. The company’s Phase 1 trial of AGT103-T, a new cell and gene therapy for HIV disease, is designed to induce durable viral suppression by delivering therapeutic genes to the recipient’s immune cells.

The cells are collected by leukapheresis, modified outside the body, then re-infused. Once infused, the cells are expected to durably suppress the virus at undetectable levels without the need for antiretroviral treatment.

“Safety represents a critical milestone in the project and gives us additional confidence that HIV can be cured,” said Jeff Galvin, CEO. “This milestone supports AGT’s mission to relieve suffering and premature death from serious human diseases. AGT’s HIV cure program is based on a platform that has the capacity to treat other chronic viral infections, as well as monogenic disorders and cancers. Our ImmunoTox program has yielded pre-clinical data showing the potential for revolutionizing solid tumor cancer treatment, and our Phenylketonuria gene therapy may be a one-and-done cure for patients suffering from that inherited disease. A success in HIV would provide sustained funding to accelerate dozens of therapeutics that are within the scope of AGT’s technology platform.”

Phase 1 in the Maryland/DC Area

AGT’s Phase 1 RePAIR (Restore Potent Antiviral Immune Responses) trial for AGT103-T is currently underway at trial sites in the Maryland / Washington, DC area. The recruitment status of the clinical trial, and information on the trial sites can be found on ClinicalTrials.gov under the identifier NCT04561258. The RePAIR trial is the company’s first step in clinical testing of cell and gene therapies for HIV, cancer, and rare diseases.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine